Chlamydia phage PhiCPG1 has been found in Chlamydia caviae in a guinea pig model for inclusion conjunctivitis, raising the possibility that Chlamydia phage is also present in patients infected with C. trachomatis (Ct). In the present study, we assayed for presence of Chlamydia phage capsid protein VP1 genes and antibodies in 84 non-Ct controls and 206 Ct patients using an enzymelinked immunoassay (ELISA), followed by verification with Western blot. None of the subjects were exposed to an antibiotic treatment or had a C. pneumoniae infection. The VP1 antibody test was positive in both, the ELISA and Western blot assay, in 4 Ct patients. PCR amplification experiments revealed presence of the VP1 gene in 5 Ct patients. The results suggest that Chlamydia phage capsid protein VP1 may exist in some Ct patients.
INTRODUCTION
Chlamydia trachomatis (Ct) is one of the common pathogens in human reproductive tract infections, accounting for 40-50% of the most prevalent sexually transmitted diseases in the world (Marrazzo et al., 2014) . Chronic chlamydial disease may lead to pelvic inflammatory disease, ectopic pregnancy, infertility and trachoma, the world's leading cause of preventable blindness (Kohlhoff et al., 2015) . Resistance to antibiotics among Ct patients poses a serious problem to treatment, especially in regions of the world where Ct infection is endemic and highly prevalent (Keegan et al., 2014) . This has led researchers to investigate the feasibility of using lytic phages to treat a Ct infection, just as bacteriophages have become an intriguing area of research as an alternative to antibiotics for other types of infection (Śliwa-Dominiak et al., 2013) .
Six species of chlamydia phage have been identified up to date: Chp1, Chp2, Chp3, φCPG1, φCPAR39 and Chp4. All 6 species could infect Chlamydia, including C. psittaci, C. abortus, C. felis, C. caviae, C. pecorum, and C. pneumoniae (Pawlikowska-Warych et al., 2015) . However, none have been shown to infect C. trachomatis. For assessment of similarity and differences between the species, two regions encoding protein VP1 and ORF4 are often used (Hsia et al., 2000; Ever son et al., 2002; Sait et al., 2011) . Garner and coworkers (2004) used VP1 monoclonal antibody 55 from Chp2 and PCR to achieve isolation, molecular characterization and the genome sequence of chlamydial bacteriophage Chp3 from C. pecorum. The capsid protein VP1 is highly conserved among different Chlamydia phage strains and mediates adhesion and entry into host cells (Hsia et al., 2000b) . The present study examined whether the phage is also present in patients with a Ct infection.
PATIENTS AND METHODS

Patients. The study was approved by the Ethics
Committee of Tianjin Medical University General Hospital (2014-YX-007). The requirement for an informed consent has been waived. The study included serum samples from 206 Ct patients and 84 non-Ct control subjects treated as ambulatory patients at our hospital between 2008 and 2010. Patients and controls had shown no significant differences in age, gender distribution, or medical history (data not shown). None of the study participants had previously received an antibiotic therapy against the Ct infection. Patients had been diagnosed with the Ct infection using the McCoy culture assay involving columnar epithelium cells from the genitourinary tract. The cervical and urethral swabs were stored in 2 sp solution (68.46 g/L sucrose, 1. 09 g/L K 2 HPO 4 , 30.9 ml/L fetal bovine serum, 50 mg/L streptomycin, 100 mg/L vancomycin, 250 mg/L amphotericin B) at -80°C. The patients' sera were initially screened in the outpatient department using a micro immunofluorescence assay to exclude patients with Chlamydia pneumoniae (Bennedsen et al., 2002) .
Culture of PhiCPG1 phage and viral genomic DNA isolation. Chlamydia caviae guinea-pig inclusion conjunctivitis (GPIC) strains containing PhiCPG1 (Tianjin Institute of Sexually Transmitted Diseases, Tianjin, China) were grown for 48 h at 37°C in a McCoy cell culture system using Dulbecco's Modified Eagle Medium. Culture supernatants were collected and centrifuged at 30 000 × g for 30 min at 4°C, and then were filtered through a 0.22-μm membrane (Schachter et 2015_1185 1994) . Filtrates were treated with DNase I (20 μg/ml) for 1 h at 37°C, and viral particles were centrifuged at 100 000 × g for 3 h at 4°C. The pellet was treated with proteinase K (200 μg/ml) for 1 h at 37°C, after which single-stranded bacteriophage genomic DNA was extracted using phenol/chloroform and precipitated with ethanol. The isolated DNA was made double-stranded using the Klenow fragment and random hexamer priming. Second-strand synthesis was confirmed using an agarose gel mobility shift assay (Maass et al., 1995) . Cloning of VP1. The double-stranded genomic DNA was digested with BamHI to yield a single linearized molecule (4.5 kb). The region encoding VP1 was amplified by PCR using the forward primer 5'-AGTAGG-GAAGCCATGGTYAGG-3' (including an NcoI site) and the reverse primer 5'-ACTGACTCGAGATTA-GAAATGATCAAT-3' (including a XhoI site). The PCR reaction (50 μl) contained 25 pmol of each primer, l mM MgSO 4 , 300 μM dNTP, and 2.5 U Platinum Pfu DNA polymerase. The following thermal cycling conditions were used: 95°C for 2 min; followed by 35 cycles of 94°C for 15 s, 58°C for 30 s, and 68°C for 2 min; and finally 68°C for 10 min (Sambrook et al., 1989) . The PCR product was checked by agarose gel electrophoresis. The gel-purified PCR product was digested with NcoI and XhoI and inserted into the pET30a(+)vector (EMD Biosciences Novagen, Beijing, China), which added an N-terminal His-tag to the VP1 sequence (pET-VP1).
Overexpression and purification of recombinant VP1. The pET-VP1 plasmid was transformed into Escherichia coli strain BL21 cells and positive clones were identified by antibiotic selection. The protein was overexpressed in BL21 cells after IPTG induction for 3 h. Recombinant VP1 was purified from inclusion bodies by lysing the cells in phosphate-buffered saline (PBS), lysozyme, and 3% Triton X-100 under sonication. The insoluble fraction was transferred to a fresh tube, resuspended in a binding buffer containing 6 M urea, and sonicated again. The suspension was analyzed by SDS-PAGE in 15% gels, run at 120 V for 1.5 h, followed by Western blotting using mouse monoclonal antibody against the His-tag and peroxidase-conjugated sheep antimouse immunoglobulin G secondary antibody (Karunakaran et al., 2002) .
After confirmation that positive clones were expressing the correct protein, the overexpression of recombinant VP1 was scaled up, and the protein was purified by nickel chelation column chromatography (CWBIO, Beijing, China). Loading and washing steps were conducted in the presence of 5 mM imidazole, and VP1 was eluted with 500 mM imidazole. Eluate was dialyzed extensively against PBS in bags with a 3.5-kDa molecular weight cutoff. Dialysate was analyzed by SDS-PAGE and Coomassie G-250 staining, and protein was quantified by band densitometry (Laughton 1984) .
Production of mouse anti-VP1 antibody. Animal experiments were approved by the Ethics Committee of Tianjin Medical University General Hospital and conducted in accordance with ARRIVE guidelines. Purified recombinant VP1 (50 μg) in incomplete Freund's adjuvant was injected intraperitoneally into BALB/c mice, followed by two booster injections at 2-week intervals. Sera were collected from inner canthal vein blood and analyzed for the presence of anti-VP1 antibodies by incubating with purified recombinant VP1 that had been fractionated by SDS-PAGE and transferred to nitrocellulose membranes. Antibody binding to VP1 was visualized using alkaline phosphatase-conjugated anti-mouse immunoglobulin G secondary antibody (Laemmli 1970 ).
Serological antibody screening for VP1 protein.
The wells of a 96-well microtiter plate were coated overnight at 4°C with 10 μg/ml recombinant VP1 in a bicarbonate binding buffer (pH 9.6). After three washes with PBS containing Tween-20 (PBST), the wells were blocked with 3% bovine serum albumin in PBST (100 μl/well) for 1 h at 37°C, and then washed again three times with PBST (Claes et al., 2012) . To identify the optimal sample dilution, serial dilutions from 1:50 to 1:6400 were prepared with immunized mouse sera as a positive control, and sera from some non-Ct subjects as a negative control, and aliquots (100 μl) of the dilutions were incubated in the wells for 1 h at 37°C. The wells were washed six times with PBST, then 100 μl of alkaline phosphatase-conjugated sheep anti-mouse (1:10,000) or anti-human immunoglobulin G secondary antibodies (1:5000) in PBST were added and incubated for 1 h at 37°C (Hackett et al., 2010) . Plates were washed six times with PBST, 100 μl pNPP substrate was added, and the plates were incubated in the dark for 30 min. Reactions were terminated by adding 50 μl of 1 M NaOH to the wells and optical density was measured at 405 nm with a microplate reader (Cohen et al., 2000) . Recombinant VP1 was subjected to SDS-PAGE separation, transferred to nitrocellulose membranes, and then probed with immunized mice sera and ELISA-positive human sera at a 1:100 dilution with TBST containing 1% bovine serum albumin (Nolen et al., 2013) . Membranes were incubated with alkaline phosphatase-conjugated sheep anti-mouse or anti-human immunoglobulin G secondary antibodies and washed. Binding was visualized using the BCIP/ NBT substrate (Sigma-Aldrich, Beijing, China).
Determination of the Vp1 gene sequence. The epithelial cells of genitourinary tract from Ct (+) and Ct (-) patient swabs were lysed and centrifuged to obtain the Ct genomic DNA. Pure solution of the Ct DNA was used as a template for a PCR reaction using primers designed based on a conserved sequence from the VP1 region of all the Chlamydia phages: forward primer 5'-CGGCGTTTGCCTTCAGT-3' and reverse primer 5'-GCGTTGCCATACGTGCTA-3' which amplify a 196 bp fragment of the VP1 gene. A phiCPG1 plasmid served as a positive control, and twice boiled water was used as a negative control. PCR amplification consisted of 11 cycles of 45 s at 94°C, 40 s at 58°C and 45 s at 72°C (with each cycle the annealing temperature was decreased by 1°C) and 20 cycles of 45 s at 94°C, 30 s at 48°C and 45 s at 72°C. The sequencing data obtained for the clinical specimens were analyzed by base sequence alignment with the target genomes of VP1us-ing a gene software and BLAST searches.
RESULTS
Cloning, expression and purification of recombinant VP1
The PhiCPG1 phage major capsid protein VP1 was cloned from cultured GPIC strains containing PhiCPG1 into the pET-30a expression plasmid. The sequence of the insert used to produce the recombinant protein is consistent with a published VP1 sequence (GenBank GeneID 1261929). This protein was overexpressed in E. coli and visualized as a single band on a SDS-PAGE gel, consistent with the expected molecular weight of 70 kDa, and used to raise antibodies in mice. This recombinant protein and the sera from immunized mice were used to design and Anti-VP1 antibody and VP1 gene in C. trachomatis infection validate ELISA and Western blot techniques to probe the sera obtained from Ct patients for the presence of anti-VP1 antibodies.
ELISA detection of anti-VP1 antibodies in Ct patients
An ELISA was designed to detect the presence of anti-VP1 antibodies in the sera from Ct patients and non-Ct controls. In initial experiments to optimize sample dilution, a dilution of 1:400 gave the greatest difference in blank-corrected OD 405 between the immunized mouse sera and non-Ct human sera (2.59-fold, Table 1 ). Therefore this dilution was used for all subsequent ELISA tests. The cutoff for a positive ELISA was defined as the sum of 10% of the average blank-corrected OD 405 for positive controls (0.035) and the average OD405 for the negative control (0.0135). The critical value (0.102) was the cutoff (0.016) plus the average background (0.086). Based on this threshold value, the ELISA detected anti-VP1 antibodies in 18 of 206 Ct patients (8.74%) and in 2 of 84 controls (2.38%; p<0.05, χ 2 test).
Western blot detection of anti-VP1 antibodies
ELISA-positive samples were subjected to Western blotting to confirm the presence of anti-VP1 antibodies. Four ELISA-positive Ct patient samples were found to be positive by a Western blot (Fig. 1) .
PCR to detect the Vp1 gene
The amplified 196 bp fragments of the VP1 gene were acquired in five Ct patient swabs (Fig. 2) . Sequencing results revealed a difference of only 4 to 5 bases between amplified fragment and the target Vp1 gene sequences. Blast analysis showed >90% coverage and similarity with Chlamydia phage phiCPG1, chp4, CPAR39, chp3, chp2. The amplified Vp1 fragment was detected in swabs of the Western blot positive patients.
DISCUSSION
Chlamydia phages have been proposed as an alternative to antibiotics to treat a Ct infection. These lytic phages infect only Chlamydia and they kill their host during growth (Hurst et al., 2000) . Out of 6 known Chlamydia phages (Sait et al., 2011) , the Chlamydia phage DNA has never been detected in either standard or clinical isolates of Chlamydia trachomatis. Of course, the associated phage may be lost during the in vitro growth. Because Chlamydia could not survive outside living cells, it is not possible to use conventional approaches for bacteriophage screening and isolation, such as plaque assays on agar plates. In the present study, we have detected a Chlamydia bacteriophage DNA and antibodies. These results confirmed a possible existence of the Chlamydia phage, as was suggested by a previous study (Garner et al., 2004) . The present study provides evidence that a small proportion of Ct patients is positive for antibodies against the major PhiCPG1 capsid protein VP1. While a few non-Ct controls also showed the presence of such antibodies, the frequency was significantly lower than among patients, and no control samples that gave a positive score in the ELISA test were also positive when examined by Western blot. Through PCR, as a simple means for screening for VP1, we successfully amplified the VP1 DNA fragment in several clinical Ct isolates. These findings provide evidence of the presence of Chlamydia phage capsid protein VP1 in urogenital Ct infection patients. These results suggest that VP1 exists in some Ct patients, and VP1 would be an optimal candidate to detect a putative Chlamydia trachomatis phage.
Further work is needed to verify that the ELISA positives in this study were not the result of, for example, IgG in human serum or impurities in the recombinant VP1 preparation used to coat the ELISA plates. As a first step towards establishing specificity, Western blotting was used to confirm all ELISA-positive samples (Alonso et al., 1990) . In the future studies, we plan to Western blotting of purified preparations of recombinant VP1 (70 kDa) using mouse or patient sera. M, molecular weight markers. Lane 1, Coomassie-stained SDS-PAGE of purified VP1. Lane 2, the same VP1 preparation as lane 1 probed using serum from unimmunized mice. Lane 3, the same VP1 preparation as lane 1 probed using serum from immunized mice. Lanes 4-6, sera from four Ct patients that tested positive for VP1 by ELISA. expand the number of patients to be screened. Also, positive clinical swabs will be added to the single density McCoy cells and subcultured several times to screen for the Chlamydia bacteriophage capsid protein VP1 antigens in Chlamydia trachomatis using immunofluorescence techniques and electron microscopy.
Our results are consistent with the existence of the Chlamydia phage capsid protein VP1 in patients infected with Ct, which is intriguing given that the phage has yet to be isolated from laboratory or clinical Ct samples. It is possible that previous in vitro studies failed to detect this phage because it is lost during cell culture, especially if the host cells are rapidly destroyed after infection. The molecular and etiological methods developed in this study can be used in future studies to search for a Chlamydia phage and help to elucidate a possible association between the Chlamydia phage and Chlamydia trachomatis.
